(Q37389541)

20 August 2017

1 reference

title

Pinpointing prognostic indicators of fungal infections in transplant patients (English)

1 reference

20 August 2017

John W Baddley

1

1 reference

20 August 2017

1 February 2009

1 reference

20 August 2017

8

1 reference

based on heuristic

inferred from page(s)

published in

Future Microbiology

1 reference

20 August 2017

4

1 reference

20 August 2017

1

1 reference

20 August 2017

77-84

1 reference

Invasive aspergillosis: epidemiology, diagnosis and management in immunocompromised patients

20 August 2017

1 reference

https://api.crossref.org/works/10.2217%2F17460913.4.1.77

Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.4.1.77

Fungal infections in the recipients of solid organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.4.1.77

Fungal infections in recipients of hematopoietic stem cell transplants: results of the SEIFEM B-2004 study--Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.4.1.77

Risks, diagnosis and outcomes of invasive fungal infections in haematopoietic stem cell transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.4.1.77

Aspergillosis case-fatality rate: systematic review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.4.1.77

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.4.1.77

Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation--a prospective, randomized, double-blind study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.4.1.77

Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.4.1.77

Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.4.1.77

Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.4.1.77

Rationale for combination antifungal therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.4.1.77

Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.4.1.77

Prognostic factors for death due to invasive aspergillosis after hematopoietic stem cell transplantation: a 1-year retrospective study of consecutive patients at French transplantation centers

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.4.1.77

Factors associated with overall and attributable mortality in invasive aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.4.1.77

A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.4.1.77

Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.4.1.77

Comparison of caspofungin and amphotericin B for invasive candidiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.4.1.77

Changes in causes of death over time after treatment for invasive aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.4.1.77

The incidence of invasive aspergillosis among solid organ transplant recipients and implications for prophylaxis in lung transplants

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.4.1.77

Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.4.1.77

A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.4.1.77

Epidemiology of fungal infections in solid organ transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.4.1.77

Attributable mortality of candidemia: a systematic review of matched cohort and case-control studies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.4.1.77

Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.4.1.77

Predictors of outcome in cancer patients with candidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.4.1.77

Association of fluconazole pharmacodynamics with mortality in patients with candidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.4.1.77

21 January 2018

Identifiers

DOI

10.2217/17460913.4.1.77

1 reference

20 August 2017

1 reference

PubMed ID

19207101